In vitro activity of the newly approved antimicrobial agent Cefiderocol against Carbapenem resistant Gram negative clinical isolates

  13 March 2024

A study assessing the in vitro activity of cefiderocol against carbapenem resistant clinical isolates compared to select antimicrobial agents, including colistin, found that 58.4% of the 77 isolates belonged to Enterobacterales, followed by P.aeruginosa and Acinetobacter spp. Three out of 45 Enterobacterales isolates were found resistant to cefiderocol, while all isolates were intermediate sensitive for colistin. Tigecycline showed good activity against Enterobacterales, followed by aztreonam. Cefiderocol is not yet available in India.

Author(s): Himanshi Khanchandani et al
Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed